Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
Each line starts at 100 so growth is directly comparable
| Metric | MMED | ATR |
|---|---|---|
| Price | $19.64 | $120.25 |
| Change today | ▼ 2.58% | ▼ 0.30% |
| Market cap | $5.53B | $7.65B |
| Return, 3 months | +30.8% | -2.8% |
| Return, year to date | – | -0.3% |
| Return, 1 year | – | -6.5% |
| P/E (TTM) | -17.4 | 21.7 |
| P/B | 1.5 | 2.9 |
| P/E percentile vs own 5y | 23rd | 11th |
| Dividend yield | – | 1.57% |
| Revenue growth (YoY, latest qtr) | +16.6% | +6.3% |
| Net profit growth (YoY) | +100.0% | -21.2% |
| Gross margin | 53.9% | 36.1% |
| Operating margin | -5.0% | 12.4% |
| Net margin | -9.7% | 9.2% |
| Return on equity | -8.7% | 13.6% |
| Analyst target vs. price | +37.5% | +35.0% |
| Analyst buy share | 100% | 75% |
| RSI (14) | 42 | 33 |
| 30-day volatility | 48.1% | 15.3% |
| Max drawdown, 1 year | -41.6% | -22.9% |
| Trend read | Strong downtrend | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
